Press release
Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic
The Key Achondroplasia Companies in the market include - BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others.DelveInsight's "Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast [https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Achondroplasia Market Report:
*
The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In November 2024, RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company focused on aptamer therapeutics, has been conducting a Phase IIa clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the low-dose (0.3 mg/kg) subcutaneous injection group (cohort 1), administered once a week, has completed treatment, showing a positive effect on the growth rate of the patients.
*
In September 2024, BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, today announced that the FDA has granted Breakthrough Therapy Designation to oral infigratinib, which is being developed for the treatment of children with achondroplasia.
*
In Febraury 2024, Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company dedicated to developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia.
*
In the United States, achondroplasia impacts a slightly higher percentage of females (51.2%) compared to males (48.8%). This slight difference may be attributed to genetic or biological factors that contribute to its somewhat greater prevalence in females.
*
In 2023, the total number of diagnosed prevalent cases of achondroplasia in Japan and the US was approximately 18,000, with expectations for this number to increase in the coming years.
*
In 2023, Japan had around 3,000 diagnosed prevalent cases of achondroplasia.
*
The epidemiology model categorizes age-specific cases into nine groups: 0-4, 5-10, 11-15, 16-20, 21-30, 31-40, 41-50, 51-60, and over 60. DelveInsight's estimates indicate that the 5-10 age group was the most affected in the US, with around 4,000 cases reported in 2023.
*
Achondroplasia is estimated to occur in 1 out of every 15,000 to 40,000 live births, making it one of the most prevalent types of skeletal dysplasia.
*
Key Achondroplasia Companies: BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others
*
Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others
*
The Achondroplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.
Achondroplasia Overview
Achondroplasia is a genetic disorder that causes abnormal bone growth, resulting in short stature and disproportionate limb size. It is the most common form of dwarfism, typically characterized by a larger head, short arms and legs, and a normal-sized trunk. The condition is caused by mutations in the FGFR3 gene, which affects the development of cartilage into bone. Individuals with achondroplasia may also experience other health issues such as joint problems, spinal abnormalities, and ear infections. Treatment focuses on managing symptoms, and while there is no cure, growth hormone therapy and other treatments can help improve quality of life.
Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/achondroplasia-market [https://www.delveinsight.com/report-store/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Achondroplasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Achondroplasia Epidemiology Segmentation:
The Achondroplasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Achondroplasia
*
Prevalent Cases of Achondroplasia by severity
*
Gender-specific Prevalence of Achondroplasia
*
Diagnosed Cases of Episodic and Chronic Achondroplasia
Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiology Forecast [https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Achondroplasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Achondroplasia Therapies and Key Companies
*
VOXZOGO (vosoritide): BioMarin Pharmaceuticals
*
Infigratinib: BridgeBio/ QED Therapeutics
*
RBM-007: Ribomic Inc
*
Recombinant human growth hormone: Changchun GeneScience Pharma
*
Infigratinib: QED Therapeutics, Inc.
*
TransCon CNP: Ascendis Pharma A/S
*
Infigratinib: QED Therapeutics, Inc
*
vosoritide: BioMarin Pharmaceuticals
*
BMN 111: BioMarin Pharmaceutical
Scope of the Achondroplasia Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Achondroplasia Companies: BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others
*
Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others
*
Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies
*
Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Achondroplasia Unmet Needs, KOL's views, Analyst's views, Achondroplasia Market Access and Reimbursement
To know more about Achondroplasia companies working in the treatment market, visit @ Achondroplasia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Achondroplasia Market Report Introduction
2. Executive Summary for Achondroplasia
3. SWOT analysis of Achondroplasia
4. Achondroplasia Patient Share (%) Overview at a Glance
5. Achondroplasia Market Overview at a Glance
6. Achondroplasia Disease Background and Overview
7. Achondroplasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Achondroplasia
9. Achondroplasia Current Treatment and Medical Practices
10. Achondroplasia Unmet Needs
11. Achondroplasia Emerging Therapies
12. Achondroplasia Market Outlook
13. Country-Wise Achondroplasia Market Analysis (2020-2034)
14. Achondroplasia Market Access and Reimbursement of Therapies
15. Achondroplasia Market Drivers
16. Achondroplasia Market Barriers
17. Achondroplasia Appendix
18. Achondroplasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=achondroplasia-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-sanofi-changchun-genescience-pharma-qed-therapeutics-inc-bridgebio-qed-therapeutics-ribomic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic here
News-ID: 3731224 • Views: …
More Releases from ABNewswire
Majewski Plumbing - Expert Plumbing Services Tailored to Villas NJ Living
Majewski Plumbing is the premier plumbing contractor near me for Cape May County, NJ. Located at Villas, NJ, the Plumbing Company provides rapid, certified plumbing services including emergency repairs, water heater installation (Rinnai specialists), winterization, and custom solutions. With 30+ years of expertise, Majewski Plumbing offers transparent pricing, comprehensive warranties, and local knowledge to reliably protect coastal homes and businesses.
The demanding nature of coastal living requires specialized plumbing [https://majewskiplumbing.com/#:~:text=WHOLE%20HOME-,PLUMBING,-CHECK%20UP] expertise,…
A Journey from Survival to Empowerment: Dr. Mildred Muhammad Shares Her Story in …
Dr. Mildred Muhammad Brings Compassion, Truth, and Global Awareness to the Reality of Domestic Abuse
Image: https://www.abnewswire.com/upload/2025/10/9a88c7e884debe817b78720c51d704ea.jpg
Washington, D.C. - On October 28 from 9 PM to 11 PM EST, Investigation Discovery (ID) and HBO Max will premiere a powerful new documentary featuring Dr. Mildred Muhammad, an award-winning global keynote speaker, author, and advocate for survivors of domestic abuse. The film shares her deeply personal journey from trauma to transformation, inspiring audiences…
Team Global Inc. Highlights the Rising Value of Job Agencies for Career Growth i …
It is a challenge to get a job in the modern competitive society. The stress of having to shine among the hundreds of applicants is a reality. However, using a job agency can provide you with a unique advantage, whether you need a temporary position, a long-term job, or a step towards something superior.
The agencies that are right not only get you jobs. They offer one-on-one assistance, offer you access…
Trusted for Quality in Kitchen Cabinets - BDE Construction & Kitchen Cabinets, S …
BDE Construction & Kitchen Cabinets is Loudon, TN's premier source for exceptional kitchen transformations. We specialize in high-quality kitchen cabinet solutions, from design to meticulous kitchen cabinet installation. Homeowners searching for reliable kitchen cabinet companies near me will find our commitment to craftsmanship and customer satisfaction unmatched. We also provide expert custom kitchen cabinet installation, ensuring a beautiful, functional.
The heart of any home is the kitchen, and at the core…
More Releases for Achondroplasia
Achondroplasia Market Predicted to See Upsurge Through 2034, Highlights DelveIns …
DelveInsight's "Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast
https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Achondroplasia Market…
Achondroplasia Market Industry Trends and Forecast to 2029
This Achondroplasia Market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain…
Achondroplasia Treatment Market Size, Share, Industry, Forecast to 2030
The Achondroplasia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Achondroplasia Treatment market. This report explores all the key factors affecting the growth of the global Achondroplasia Treatment market, including…
Achondroplasia Treatment Market to witness Great Growth in Forecast to 2030
The professional report on The Achondroplasia Treatment Market research provides valuable insights on business size, ongoing trends, drivers, potential risks, outcomes, and significant segments. Additionally, the Industry Report presents precise assumptions to forecast future market growth. Drawing from industry experts, the report's findings offer actionable measures that help readers develop effective strategies for the Achondroplasia Treatment market's future growth. Furthermore, the research provides a comprehensive view of present market needs…
Achondroplasia Market: Pipeline Review, H2 2022
HTF Market Intelligence released a new research report of 60 pages on title 'Achondroplasia - Pipeline Review, H2 2022' with detailed analysis, forecast and strategies. The market Study is segmented by key a region that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources. This section also provides the scope of different…
Achondroplasia (Musculoskeletal) Market Competitive Research And Global Outlook …
The Achondroplasia (Musculoskeletal) Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Achondroplasia (Musculoskeletal) market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Achondroplasia (Musculoskeletal) market. Importantly, it allows players to gain deep insights into…
